
FAQs: Inside the AUA’s updated recurrent UTI guideline
These FAQs outline key updates to the AUA's guideline on recurrent uncomplicated urinary tract infections in women.
On September 4, 2025, the American Urological Association (AUA), in partnership with the Canadian Urological Association (CUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2025 amendment to the Recurrent Uncomplicated Urinary Tract Infections (rUTI) in Women Guideline.1
The guideline, which includes 20 statements, is intended to aid clinicians in diagnosing, treating, and managing women with recurrent episodes of localized cystitis restricted to the lower urinary tract. The amendment adds new recommendations on non-antibiotic prophylaxis and symptom evaluation; updates the introduction to define new and existing guideline terms and to address emerging diagnostics; expands the future directions section to cover potential new treatment alternatives and molecular technologies; and revises the guideline algorithm.
"In updating the 2025 Guideline Update for Recurrent Uncomplicated Urinary Tract Infections (rUTI) in Women, we hope to take a more patient-centered, risk-based and microbiome-aware approach to rUTI management," said Guideline Amendment Chair A. Lenore Ackerman, MD, PhD, director of research for the Division of Urogynecology and Reconstructive Pelvic Surgery at the University of California, Los Angeles, in the AUA press release.2 "The updated Guideline tries to balance diagnostic accuracy with clinical judgment, redefining treatment success as symptom resolution rather than microbial eradication and placing a premium on antimicrobial stewardship and patient-centered care. These changes reflect a maturing understanding of the urinary microbiome, the limitations of existing diagnostics and a public health imperative to reduce unnecessary antibiotic exposure."
In an interview with Urology Times®, Ackerman discussed the key changes and how clinicians can apply them in practice.
1. How does the amendment define treatment success?
According to Ackerman, the amendment redefines treatment success as symptom resolution rather than microbial eradication. She noted that this does not represent a major departure from prior practice, because the guideline has long focused on patients' symptoms and primary complaints. The renewed emphasis reflects the arrival of new testing approaches, which have raised questions from both patients and clinicians about how to interpret results.
"We really wanted to make sure to bring that focus back to the idea that we treat patients and not tests, and that if patients don't have symptoms, there's no need to treat them, and if they do have symptoms, we should be focused on managing the symptoms, regardless of what our tests say," Ackerman said.
2. What initial evaluation does the guideline recommend for women presenting with rUTIs?
Clinicians should obtain a complete patient history and perform a pelvic examination in women presenting with rUTIs (Clinical Principle). Urinalysis, urine culture, and sensitivity should be obtained with each symptomatic acute cystitis episode before treatment is initiated (Moderate Recommendation; Evidence Level: Grade C).
When an initial urine specimen is suspected of contamination, clinicians should obtain repeat urine studies, with consideration for a catheterized specimen (Clinical Principle). Cystoscopy and upper tract imaging should not be routinely obtained in the index patient presenting with rUTI (Expert Opinion).
3. What is required to make a diagnosis of rUTI, and what role does a negative urinalysis play?
To diagnose rUTI, clinicians should document evidence of inflammation (pyuria) and the presence of uropathogenic bacteria in association with symptomatic episodes (Clinical Principle).
Ackerman explained that growing understanding of the urinary microbiome has made the traditional definition of infection, ie, bacteria present in a sterile location, less useful, because bacteria are likely present in the bladder of nearly everyone. Inflammation is one reliable way to distinguish infection from a normal bacterial complement.
“I hope people look at [a negative urinalysis] that way—as a helpful tool to add to their ability to better interpret what's going on with the patient,” she explained. "If a urinalysis is completely devoid of any signs of inflammation, then it seems very unlikely that their body is having a negative reaction to the bacteria that maybe you found on a culture.”
Ackerman cautioned that a positive urinalysis still carries limited value, because white blood cells may be present for many reasons other than infection. However, a pattern of negative urinalysis with a positive culture should prompt clinicians to consider conditions that mimic UTI and to broaden the differential diagnosis rather than repeatedly treat with antibiotics.
4. How should clinicians manage asymptomatic bacteriuria in women with rUTIs?
Clinicians should omit surveillance urine testing, including urine culture, in asymptomatic patients with rUTIs (Moderate Recommendation; Evidence Level: Grade C), and should not treat asymptomatic bacteriuria (Strong Recommendation; Evidence Level: Grade B).
Ackerman noted that when a patient presents with a positive test but otherwise feels well, clinicians should recognize that the result may be a false positive or may be positive for reasons unrelated to disease.
5. What antibiotic treatment does the guideline recommend for acute cystitis episodes?
Clinicians should use first-line therapy (ie, nitrofurantoin, trimethoprim-sulfamethoxazole [TMP-SMX], or fosfomycin), dependent on the local antibiogram, to treat symptomatic UTIs in women (Strong Recommendation; Evidence Level: Grade B). Patients with rUTIs experiencing acute cystitis episodes should be treated with as short a duration of antibiotics as reasonable, generally no longer than 7 days (Moderate Recommendation; Evidence Level: Grade B).
When urine cultures are resistant to oral antibiotics, clinicians may treat with culture-directed parenteral antibiotics for as short a course as reasonable, generally no longer than 7 days (Expert Opinion). Clinicians may also offer patient-initiated (self-start) treatment to select patients with rUTIs experiencing acute episodes while awaiting urine cultures (Conditional Recommendation; Evidence Level: Grade C).
6. Where does antibiotic prophylaxis fit in rUTI prevention?
Following discussion of the risks, benefits, and alternatives, clinicians may prescribe antibiotic prophylaxis to decrease the risk of future UTIs in women of all ages previously diagnosed with UTIs (Conditional Recommendation; Evidence Level: Grade B).
Ackerman acknowledged that low-dose antibiotic prophylaxis has the strongest supporting data, but she noted that clinicians must weigh individual and societal risks, including antibiotic resistance, allergies, antibiotic-associated diarrhea, and emerging, not yet well-defined data on potential long-term health effects. She added that in focus groups, patients with rUTIs "often express a lot of discomfort with the amount of antibiotics that they've needed or gotten."
7. What does the amendment recommend regarding non-antibiotic prophylaxis?
The amendment includes new recommendations on non-antibiotic prophylaxis. Clinicians should offer cranberry as an option for prophylaxis in women with rUTIs (Moderate Recommendation; Evidence Level: Grade B) and may offer methenamine hippurate (Conditional Recommendation; Evidence Level: Grade C). When women with rUTIs have a water intake below 1.5 L/day (50 oz), clinicians may offer increased water intake for prophylaxis (Conditional Recommendation; Evidence Level: Grade C).
Ackerman said that although current data cannot establish that cranberry prophylaxis is equivalent to a low-dose daily antibiotic, accumulating evidence suggests that some non-antibiotic approaches may be at least noninferior, and they carry a different and often minimal risk profile.
Speaking from her own practice and not on behalf of the guideline committee or the AUA, she said that because cranberry and methenamine have performed well in head-to-head comparisons with low-dose antibiotic prophylaxis, "I think it's very reasonable to put them on the same level and say that we should be having these discussions, engaging in shared decision-making with our patients about what their priorities are and what they want to do."
She also noted that patients who start with one approach can switch to an alternative form of prophylaxis if it is not effective for them.
8. Why does the guideline advise that D-mannose alone may not be effective?
Clinicians should inform patients with rUTIs that D-mannose alone for prophylaxis may not be effective in UTI prevention (Moderate Recommendation; Evidence Level: Grade B).
Ackerman explained that since the previous guideline update, a larger clinical trial did not demonstrate efficacy for D-mannose over the comparator arm.3 However she emphasized that the recommendation is not intended to discourage use, given the low likelihood of adverse effects.
"If they have been using it and using it successfully, there's no reason that they cannot continue to do so," she said. Instead, D-mannose should be used in combination with another agent, such as increased hydration, rather than as the sole form of prophylaxis.
9. What follow-up does the guideline recommend after treatment?
Clinicians should not perform a post-treatment test-of-cure urinalysis or urine culture in asymptomatic patients (Expert Opinion). When UTI symptoms persist following antimicrobial therapy, clinicians should repeat urine cultures to guide further management (Expert Opinion). For patients with persistent symptoms after microbiological cure, clinicians should evaluate for alternative causes (Expert Opinion).
10. How should clinicians approach vaginal estrogen therapy in perimenopausal and postmenopausal women?
In perimenopausal and postmenopausal women with rUTIs, clinicians should recommend vaginal estrogen therapy to reduce the risk of future UTIs if there is no contraindication (Moderate Recommendation; Evidence Level: Grade B).
For women in whom hypoestrogenization of the vaginal and genitourinary tissues may contribute to UTI susceptibility, Ackerman said "it seems like a no brainer to me that estrogen would be my first line if people are willing to do it." She identified misinformation about hormones in general as the primary barrier and said she often shares the American College of Obstetricians and Gynecologists position statement on vaginal estrogen, including its use in patients with a personal history of breast cancer. She also counsels patients that systemic absorption is minimal and that benefits extend to bladder health, sexual function, and vaginal health.
Ackerman added that systemic hormone therapy is usually insufficient to restore genitourinary tissues to their premenopausal state. If a patient has atrophy or thinning of those tissues, "there is no reason those things can't be given together," she said, noting that the AUA guideline on genitourinary syndrome of menopause also addresses this issue. Because response to standard vaginal estrogen dosing varies, she recommended flexibility based on the patient's symptoms and tissue findings.
11. What barriers may clinicians face in adopting the updated recommendations?
Ackerman identified the structure of care delivery as the biggest obstacle. Patients in acute distress want rapid relief, and physicians with double- and triple-booked schedules have limited capacity to fit in evaluations, which leads many patients to walk-in clinics.
She emphasized that for patients with multiple UTIs each year, prevention should take priority over repeated intermittent antibiotic courses.
"We can't just keep slapping the band aids on," she emphasized. “We should be doing something more proactive to get patients in to make sure they really have UTIs and when they do, make sure they're getting appropriate prevention. Because the bulk of the data seems to suggest now that intermittent courses of antibiotics without prevention has much more in terms of negative consequences for people than actually trying some of these preventative approaches.”
_____
REFERENCES
1. Ackerman AL, Bradley M, D'Anci KE, Hickling D, Kim SK, and Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2025. doi:10.1097/JU.0000000000004723
2. American Urological Association Release Recurrent Uncomplicated Urinary Tract Infections in Women Guideline Amendment. News release. American Urological Association. September 4, 2025. Accessed November 9, 2026.
3. Hayward G, Mort S, Hay AD, et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(6):619-628. doi:10.1001/jamainternmed.2024.0264
Related to this article







